Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial

BACKGROUND: Solid tumors, such as hepato-pancreato-biliary cancer, develop tumor hypoxia with tumor growth. Despite advances in surgery, a majority of these patients are in an unresectable condition. At this stage standard cytotoxic chemotherapy regimens are applied with limited success. Novel biolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Limani, Perparim, Linecker, Michael, Kron, Philipp, Samaras, Panagiotis, Pestalozzi, Bernhard, Stupp, Roger, Jetter, Alexander, Dutkowski, Philipp, Müllhaupt, Beat, Schlegel, Andrea, Nicolau, Claude, Lehn, Jean-Marie, Petrowsky, Henrik, Humar, Bostjan, Graf, Rolf, Clavien, Pierre-Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070093/
https://www.ncbi.nlm.nih.gov/pubmed/27756258
http://dx.doi.org/10.1186/s12885-016-2855-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070093/
https://www.ncbi.nlm.nih.gov/pubmed/27756258
http://dx.doi.org/10.1186/s12885-016-2855-3

Ejemplares similares